Living with metastatic breast cancer can make Pinktober feel complicated. One patient reflects on awareness, research, loss and remembering the people behind the pink.
|Articles|September 8, 2008
- Fall 2008
- Volume 7
- Issue 3
International Thyroid Cancer Survivors' Conference
Author(s)Elizabeth Whittington
Educational conference for thyroid cancer patients, survivors, and caregivers.
Advertisement
The Thyroid Cancer Survivors’ Association will feature more than 50 speakers and more than 80 sessions at its annual conference. The educational gathering offers an opportunity to learn about advances in treatment and follow-up care, insurance and employment issues, coping skills, clinical trials, and more. The conference will be held October 17-19 in St. Louis, Missouri. Find details at
Articles in this issue
about 18 years ago
Message from the CURE Staffabout 18 years ago
Understanding Preventive Mastectomyabout 18 years ago
Breaking Down TCMabout 18 years ago
Olympian Postpones Treatment to Competeabout 18 years ago
New Pharmacy Breed Offers Special Attention, Drawbacks to Patientsabout 18 years ago
www.SharingHope.tvabout 18 years ago
Q&A: Vitamin Dabout 18 years ago
Web Exclusive: Preventing Breast Cancerabout 18 years ago
Never Fearabout 18 years ago
Web Exclusive: How to Manage Side EffectsAdvertisement
Related to this article
A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.
Learn how nipple-sparing mastectomy, including endoscopic approaches, may help preserve appearance, reduce scarring and support breast cancer recovery.
After 17 and a half years with metastatic primary peritoneal cancer, a former hospital executive explains how an AI health agent helped her after discharge.
Relatives of people with BRCA1 or BRCA2 variants completed genetic testing more often when a navigator reached out directly than when they received a letter.
The FDA approval is based on the phase 3 BRUIN CLL-313 trial, in which 94% of patients responded to Jaypirca compared with 81% who received chemoimmunotherapy.
Giredestrant plus Afinitor lowered the risk of cancer worsening or death by 62% in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer.
Five-year results presented at ASTRO 2026 show a five-week radiation schedule after prostatectomy controls cancer as well as a seven-week course. But serious urinary side effects were more common.
Advertisement
Advertisement
Trending on CURE
1
Radiation Oncologist Answers Top Questions About Radiation Therapy
2
5 Years of Breast Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
3
Former Hospital Executive on Risks Patients With Cancer Face After Discharge
4
10 Cancer Treatment Approvals From September 2026 and What They Mean for You
5